Kathleen Rickard

Dr. Rickard, who has served as the Chief Medical Officer since February 2019, brings 25 years of experience in clinical research in respiratory medicine, industry, and management.

Prior to joining Verona Pharma, Dr. Rickard served in multiple roles at Aerocrine and subsequently Circassia, where she was instrumental in directing clinical and regulatory strategies for NIOX VERO, an airway inflammation test for managing asthma, across key markets such as the US, China, and Japan, as well as the rest of the world. Previously, Dr. Rickard was Vice President of Clinical Development and Medical Affairs of GlaxoSmithKline’s Respiratory Medicines Development Centre and, over a period of 15 years, held a number of other leadership positions in clinical development across GlaxoSmithKline’s global respiratory franchise. Dr. Rickard received an MD from Hahnemann University Hospital, Philadelphia.